ERBB2 and gastroesophageal junction adenocarcinoma: In China, for first‐line treatment of HER2‐positive advanced gastric or GEJ adenocarcinoma, the PEM + TRAS + Chemo regimen is not cost‐effective when compared to the TRAS + Chemo regimen, unless the price of pembrolizumab is reduced.